Article Text

SAT0070 Levels of 14-3-3Eta Predict Good Eular Response to Anti-TNF Treatment in Patients with Rheumatoid Arthritis
  1. A. Marotta2,
  2. W.P. Maksymowych1
  1. 1U of Alberta, Edmonton
  2. 2Augurex, Vancouver, Canada


Background 14-3-3eta (η) is a mechanistic biomarker that, as a soluble ligand, dose-dependently induces key joint damage and inflammatory factors, including TNF-alpha (α). There is a high clinical unmet need in RA to identify markers that inform the likelihood of response to biological therapies, given the heterogeneity of patient response. We have previously reported that 14-3-3η marks response to TNFα therapy and postulate that the potent induction of TNFα by 14-3-3η may diminish the efficacy of standard anti-TNF doses in some patients or over time in the same patient.

Objectives This study evaluates whether various 14-3-3η cut-offs better inform the likelihood of a good EULAR response to anti-TNFs.

Methods Serum 14-3-3η was measured in a cohort of 74 RA patients who were candidates for anti-TNF therapy; all patients were refractory to standard DMARDs. Median patient age was 59 years and 73% were female. Pre-treatment 14-3-3η levels were measured on the Augurex 14-3-3η ELISA and EULAR classification criteria were used to define Good response to anti-TNF therapy. Two-tailed Mann-Whitney U-tests were used to assess group differences between Good and inadequate responders. Three 14-3-3η concentration cut-offs were selected as follows: the reported manufacturer's reference range ≥0.19 ng/ml as well as 2 and 4 times that level, namely 0.40 and 0.80 ng/ml. To assess 14-3-3η's association with a Good EULAR response, Fisher's exact test and stepwise multivariate analyses were used. Variables included in the model were age, gender, disease duration, HAQ, CRP, and DAS28-ESR.

Results Median 14-3-3η levels were significantly lower in patients who achieved a Good EULAR response compared to inadequate responders, 2.52 ng/ml (0.79 - 20) vs 0.72 ng/ml (0 - 7.01), p<0.03. Fishers' exact test revealed that the two lower 14-3-3η cut-offs were associated with a higher odds (OR) of a achieving a Good EULAR response to anti-TNF therapy. For patients with 14-3-3η levels ≤0.19ng/ml, the OR (95%CI) was 9.3 (1.9 - 45.4), p<0.008; ≤0.40 ng/ml was 9.5 (2.4 - 37.1), p<0.002; ≤0.80 ng/ml was 3.4 (1.0 - 10.8), p<0.05. Multivariate analysis revealed that 14-3-3η, at all 3 cut-offs, was the only independent predictor of a Good EULAR response with the ≤0.40 ng/ml being the strongest predictor of response to anti-TNF therapy with a likelihood ratio of 10.2, p=0.0014 yielding an R2 of 18%.

Conclusions Consistent with 14-3-3η's pathophysiological mechanism as an upregulator of TNFα, higher 14-3-3η levels are clinically associated with a lower likelihood of response to anti-TNF therapy. 14-3-3η may inform anti-TNF dosing/administration strategies to optimize response to therapy.

Disclosure of Interest A. Marotta Employee of: Augurex Life Sciences Corp, W. Maksymowych Consultant for: Augurex Life Sciences Corp

DOI 10.1136/annrheumdis-2014-eular.3426

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.